Richard B Weininger, M.D. Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 125 Millbrook Road, Hudson, NY 12534 Phone: 914-388-0800 Fax: 518-751-1531 |
Duy Q. Vu, M.D. Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 69 Prospect Ave, Hudson, NY 12534 Phone: 518-822-8484 Fax: 518-822-9335 |
Linda Demarco, M.D. Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 69 Prospect Ave, Hudson, NY 12534 Phone: 518-822-8484 Fax: 518-822-9335 |
News Archive
Scientists from the Tumor Immunotherapy and Microenvironment research group led by Dr Bassam Janji at the Luxembourg Institute of Health Department of Oncology, and the Swedish pharma company Sprint Bioscience published the results of an innovative approach that turns "cold" tumors "hot". "Cold", immune-desert tumors are classically immunotherapy-resistant.
The human immune defense is based on the ability of white blood cells to accurately identify disease-causing pathogens and to initiate a defense reaction against them.
Five years after diagnosis, only 40 percent of patients with locally-advanced oral cavity cancer will still be alive. The question is who is likely to live and who is likely to die? The answer to this question could not only help patients better predict the course of their disease, but could help doctors choose the most appropriate post-surgical treatments - patients at highest risk could receive the most aggressive combinations of radiation and chemotherapy.
More than one in ten COVID-19 patients in 314 UK hospitals caught the infection in hospital during the first pandemic wave say researchers conducting the world's largest study of severe COVID-19.
A protein that governs development of human embryonic stem cells (hESCs) also inhibits the growth and spread of malignant melanoma, the deadliest skin cancer, Northwestern University researchers have discovered.
› Verified 2 days ago